AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
The biotech world was buzzing this past week about the judgment against Cambridge-based Transkaryotic Therapies Inc., declaring the company had infringed on several patents held by Thousand Oaks, Calif.-based Amgen Inc. for an erythropoietin-based drug for anemia patients.
In this case, the stakes were high for Amgen, which holds the lion's share of a $4 billion worldwide market with its version of the drug, Epogen.
And after last Friday's court ruling, it would appear that hefty share of the market is safe. Consequently, Amgen's stock price was inching its way back up this past week to a 52-week high of $80.44, while TKT's stock price was trading below its …